Un­sealed doc­u­ments de­tail Bio­gen's fight against San­doz Tysabri biosim­i­lar

San­doz is hop­ing to cel­e­brate its re­cent­ly an­nounced spin­off from No­var­tis with swift ap­provals for its Tysabri biosim­i­lar in both the US and Eu­rope — but not if Bio­gen can help it.

Bio­gen filed suit against San­doz ear­li­er this month, ac­cus­ing the com­pa­ny of at­tempt­ing to “reap the ben­e­fits of Bio­gen’s hard work and suc­cess” by al­leged­ly in­fring­ing on Tysabri’s patent rights.

“Bio­gen has ap­plied for and ob­tained a wide va­ri­ety of is­sued patents cov­er­ing its in­ven­tions re­lat­ing to Tysabri, in­clud­ing re­gard­ing ther­a­peu­tic us­es of Tysabri, ways of mak­ing treat­ment with Tysabri safer for pa­tients and Bio­gen’s in­no­v­a­tive meth­ods of man­u­fac­tur­ing an­ti­bod­ies, such as Tysabri,” the com­pa­ny said in a 107-page redact­ed com­plaint, un­sealed on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER